Sentynl Therapeutics, Inc. v. U.S. Specialty Insurance Co

21-55370

March 09, 2022
Drugmaker's Opioid Probe Costs Not Covered, 9th Circ. Says

U.S. Specialty Insurance Co. has no obligation to cover more than $4 million in costs an opioid drugmaker said it incurred while responding to a U.S. Department of Justice investigation, the Ninth Circuit affirmed on Wednesday, citing a broad exclusion for claims relating to the company's products.
January 11, 2022
9th Circ. Skeptical Of Coverage For Co.'s Opioid Probe Costs

A Ninth Circuit panel seemed poised to secure U.S. Specialty Insurance Co.'s win in a coverage dispute with an opioid drugmaker seeking to recover $2.4 million it spent responding to government subpoenas, with one judge saying that the language of a key exclusion was broad but unambiguous.
September 17, 2021
Insurer Asks 9th Circ. To Affirm Opioid Coverage Dispute Win

U.S. Specialty Insurance Co. urged the Ninth Circuit on Friday to uphold a finding that a California pharmaceutical company wasn't entitled to coverage of costs it incurred as part of an investigation into the company's opioid drugs and marketing practices.
July 13, 2021
Pharma Co. Asks 9th Circ. To Revive Opioid Coverage Dispute

A California pharmaceutical company asked the Ninth Circuit to revive a directors and officers coverage dispute, saying its insurer misapplied a goods and products exclusion to avoid covering an investigation into the company's sales and marketing practices.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:

Law360